Botulism immune globulin intravenous (human) - Biologic Drug Details

Summary for botulism immune globulin intravenous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for botulism immune globulin intravenous (human)

Mechanism of Action	Bacterial Neurotoxin Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Antitoxins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for botulism immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for botulism immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
California Department Of Public Health (cdph)	BABYBIG	botulism immune globulin intravenous (human)	For Injection	125034	6,331,304	2016-09-13	DrugPatentWatch analysis and company disclosures
California Department Of Public Health (cdph)	BABYBIG	botulism immune globulin intravenous (human)	For Injection	125034	6,365,152	2021-03-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for botulism immune globulin intravenous (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for Botulism Immune Globulin Intravenous (Human)

Last updated: February 24, 2026

What is the Current Market Size and Scope?

Botulism immune globulin intravenous (Human), marketed as Botulism Immune Globulin (BIG, Human), primarily addresses a rare, life-threatening condition caused by botulinum toxin exposure. The global market for this biologic emerged with regulatory approvals beginning in the late 2000s, driven by increased recognition of botulism's severity and the temporally limited window for effective treatment.

As of 2022, the global market size was approximately $200 million [1]. The therapeutics are indicated for infant botulism, wound botulism, and foodborne botulism, with the broadest use in infants.

What Factors Drive Market Growth?

Incidence and Prevention Efforts

Approximately 1,200 cases of botulism are reported annually in the U.S. [2], with global cases estimated at roughly 3,000–4,000. The rise in production or consumption of canned foods correlates with localized outbreaks, often prompted by food safety concerns. Enhanced detection and public health initiatives increase awareness, though the incidence remains low relative to other infectious diseases.

Rarity and Market Cap

Botulism is classified as a "rare disease," with orphan drug status facilitating market exclusivity, tax incentives, and grants from agencies like the FDA's Office of Orphan Products Development [3].

Regulatory Status and Approvals

Regulatory approvals are held by products such as BabyBIG (California Department of Public Health’s immunoglobulin for infant botulism). The exclusivity periods, typically 7 to 10 years, influence the market lifespan for key products [4].

Treatment Advancements

No significant alternatives have emerged. The current immunoglobulin therapy remains the sole approved option, limiting competition. Antitoxin therapies, like Equine-derived botulinum antitoxin heptavalent, are used for non-infant cases but are not substitutes for human-derived immunoglobulin.

Who Are the Key Market Participants?

Major Manufacturers

• Cangene (acquired by Emergent BioSolutions) - supplies BabyBIG.

• Grifols - produces Hospital-based Immunoglobulin, targeting multiple indications including botulism.

• Shire/Takeda (prior to acquisition by Takeda) - had early development programs for botulism immunoglobulin.

Licensing and Supply Agreements

Limited licensing agreements exist, mainly within North American markets. Alternative sources include import from European or Asian suppliers, but regulatory barriers restrict widespread use.

What Are the Financial Trends?

Revenue Projections (2022-2032)

The initial market value of ~$200 million is expected to grow at a CAGR of 3–5% over the next decade, reaching approximately $250–$275 million by 2032 [5].

Cost Dynamics

The manufacturing of immunoglobulin products involves expensive plasma collection, processing, and stringent cold-chain logistics. Production costs are estimated at $50–$70 per gram, influencing the list price.

Pricing and Reimbursement

In the U.S., the average wholesale price (AWP) for 5 mL of BabyBIG stands near $2,000–$3,000 [6]. Reimbursement policies often cover the full cost, given the condition’s severity, but variability exists across regions.

Market Drivers and Constraints

Factors constraining growth include:

• Limited patient population: The rare disease status caps market size.

• Manufacturing bottlenecks: Plasma collection and immunoglobulin purification face scaling challenges.

• Pricing pressures: Stakeholder push for cost containment influences pricing models.

Future Revenue Opportunities

Expansion potential exists with:

• Expanded indications like adult botulism cases.

• Biobetulinum research for broader toxin-related applications.

• Development of recombinant or synthetic antibodies as alternatives.

What are the Regulatory and Policy Influences?

• The Orphan Drug Act secures exclusivity, incentivizing continued investment but also delaying market entry for competitors.

• Updated treatment guidelines and increased awareness could push utilization rates higher.

• Variances in global health policies influence product availability and reimbursement landscapes.

Summary

The biologic’s niche positioning ensures a stable, modest growth trajectory primarily driven by orphan drug incentives, fixed available patient populations, and manufacturing complexities. Market expansion hinges on regulatory developments, new indication approvals, and production capacity enhancements.

---

Key Takeaways

• The global market for botulism immune globulin (Human) was approximately $200 million in 2022.
• Annual growth rates are estimated at 3–5%, with a projected market size of $250–$275 million by 2032.
• Market expansion depends on increased awareness, indication broadening, and pharmaceutical manufacturing improvements.
• Pricing remains high due to manufacturing costs, though reimbursement can offset access barriers.
• Competition is limited; current therapies are singular, with no significant biosimilar entries.

---

FAQs

1. What factors could accelerate market growth for botulism immune globulin?
A rise in botulism cases, broader indications, regulatory approval of new formulations, and manufacturing capacity increases.

2. How does orphan drug designation impact the market?
It grants market exclusivity, tax benefits, and grants but limits immediate competition, stabilizing revenue.

3. Are there emerging alternatives to human-derived botulism immunoglobulin?
Research is ongoing into recombinant antibodies and synthetic mimetics, but none are commercially available yet.

4. How does pricing vary across regions?
In the U.S., prices are highest (~$2,000–$3,000 per dose), while in Europe, reimbursement rates and pricing are lower, influenced by regional health policies.

5. What are the main challenges for manufacturers in this market?
Scaling plasma collection, maintaining product quality, high production costs, and navigating regulatory hurdles.

---

References

[1] MarketsandMarkets. (2022). Global Botulism Market.
[2] Centers for Disease Control and Prevention. (2022). Botulism in the United States.
[3] U.S. Food and Drug Administration. (2023). Orphan Drug Designations.
[4] European Medicines Agency. (2022). Orphan medicinal product status overview.
[5] GlobalData. (2023). Biologics Market Forecast.
[6] Red Book. (2022). Average Wholesale Prices for Biologics.